Continuous THC Infusion in Four Monkeys Produced Delayed Disruption After Withdrawal

A 1986 study in four rhesus monkeys found that food-maintained responding could remain largely stable during continuous THC infusion but fall after it stopped. Little overt disruption during exposure did not rule out a later withdrawal-associated change.

The timing was part of the finding

Response-rate reductions generally emerged after a delay and could persist beyond a week in the initial experiments. That is a description of this infusion model, not a standard timeline for human cannabis withdrawal.

Re-exposure supplied another comparison

In a later phase, resuming THC halted the withdrawal-associated rate decreases, and stopping it again was followed by another decrease. The authors used this pattern to support a dependence interpretation. It did not directly measure subjective distress or every component of a clinical use disorder.

The model had substantial boundaries

The sample was small and exposure was continuous and intravenous. The investigators also repeated initial observations with lower solvent concentrations. These details matter when considering formulation effects and the limits of translating an experimental regimen to ordinary cannabis use.

Interpreting the evidence

This experiment separates on-drug behavior from behavior after discontinuation. It does not establish that every tolerant user is dependent or that a stable response rate during exposure proves absence of later withdrawal. Species, dosing method and the actual task remain essential.

Related reading: interpreting cannabis tolerance claims.

Research reference

Beardsley PM; Balster RL; Harris LS (1986). Dependence on tetrahydrocannabinol in rhesus monkeys. The Journal of pharmacology and experimental therapeutics. PubMed research record.

This analysis draws on the supplied study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

A 2017 drug-discovery report described APD371, a selective CB2 agonist, maintaining its effect during a five-day rat osteoarthritis-pain protocol. That short preclinical finding is different from established long-term clinical efficacy. The report concerned selection of a development candidate The authors considered receptor efficacy, pharmacokinetics and pharmaceutical properties alongside an oral…

Spread the love

Read Article: APD371 Maintained a Pain-Response Effect for Five Days in a Preclinical Development Study

Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

A 2021 rat study found sustained pain-response effects with JWH133 while another CB2 agonist lost efficacy after two days under its repeated-treatment protocol. Shared receptor targeting did not establish equal durability. The compounds were compared in a defined model The experiment used chemically induced osteoarthritis and measured pressure responses and…

Spread the love

Read Article: Two Biased CB2 Agonists Had Different Durability in a Rat Osteoarthritis Experiment

An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

A 2021 review argued that acute neurocognitive responses to cannabis vary with biological, pharmacological and exposure-related factors. A product label or use-frequency category alone cannot capture all the determinants discussed. The review considered interacting sources of variation It discussed brain-network activity, formulation, use frequency and differences between therapeutic and recreational…

Spread the love

Read Article: An Acute Cannabis Review Treated Neurocognitive Response as a Multi-Factor Question

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us